Merck’s Suvorexant Driving Claims May Get Green Light After Lunesta Re-Label
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA signals comfort with declaring low dose of at least one insomnia product as OK for next-day driving, but suvorexant’s fate will depend on Merck’s data.